Physician profile
Peter D Analytis
NPI 1720032311
$1,553.57
in general payments reported to CMS, 2019-2025
26 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $172 · 2021: $66.93 · 2022: $95.40 · 2023: $182 · 2024: $504 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $294.36 | 2019-2025 | Xywav |
| Avadel Cns Pharmaceuticals, LLC | $197.31 | 2024 | Lumryz |
| Sunovion Pharmaceuticals INC. | $159.55 | 2019-2020 | |
| Abbvie INC. | $109.06 | 2021-2024 | |
| Eisai INC. | $88.45 | 2024 | |
| Axsome Therapeutics, INC. | $79.06 | 2023-2025 | Sunosi, Symbravo |
| Catalyst Pharmaceuticals, INC. | $55.83 | 2024 | |
| Novartis Pharmaceuticals Corporation | $54.41 | 2019-2025 | |
| Harmony Biosciences LLC | $54.32 | 2023-2024 | Wakix |
| Lilly USA, LLC | $50.51 | 2019-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $49.81 | 2019-2020 | |
| Shire North American Group INC | $46.61 | 2019 | |
| Philips North America LLC | $45.33 | 2019 | |
| Greenwich Biosciences, INC. | $42.05 | 2019 | |
| Amneal Pharmaceuticals LLC | $30.98 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.51 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $22.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $21.11 | 2020 | |
| Emd Serono, INC. | $19.71 | 2020 | |
| Genzyme Corporation | $17.64 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.16 | 2025 | Purified Cortrophin Gel |
| Neurocrine Biosciences, INC. | $16.57 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $16.12 | 2019 | |
| Corcept Therapeutics | $14.10 | 2019 | |
| Glaxosmithkline, LLC. | $13.96 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Analytis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.